MINNEAPOLIS, MINNESOTA--(Marketwire - Sept. 27, 2012) - DiaMedica (TSX VENTURE:DMA) today announces that it has been selected to present a Late Breaking Science Poster featuring pre-clinical cardiovascular data on DM-204 at the 2012 American Heart Association's Scientific Sessions being held in Los Angeles, CA, November 3-7, 2012.
Mark Williams, PhD., Vice President of Research at DiaMedica will present the poster presentation titled, "A Novel Bradykinin-2 Receptor Agonist Antibody that Improves Diabetic and Cardiovascular Endpoints." DiaMedica is developing DM-204 for the treatment of diabetes and cardiovascular disease.
"We are delighted to have the opportunity to share the results and mechanism of our G-protein coupled receptor agonist antibody," commented Rick Pauls, Chairman and CEO of DiaMedica. "Cardiovascular disease is a major complication of diabetes and the leading cause of early death among people with diabetes. DM-204 could be a promising treatment for diabetes and cardiovascular disease if it shows the benefit in future human trials."
DiaMedica is a biopharmaceutical company focused on discovery and development of novel therapeutic compounds for diabetes and other major, medically-unmet diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in significant improvement in blood glucose control and HbA1c levels and also significant decreases in blood pressure and serum cholesterol.
DiaMedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10 Cardiovascular/Metabolic Projects to Watch". The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.
Caution Regarding Forward-Looking Information
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.